Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FTRENASDAQ:LFSTNASDAQ:PINCNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFTREFortrea$4.46+8.0%$5.55$3.97▼$28.41$403.63M2.151.81 million shs837,836 shsLFSTLifeStance Health Group$5.98+1.7%$6.31$4.64▼$8.61$2.33B1.31.59 million shs456,219 shsPINCPremier$22.99+0.6%$20.97$17.23▼$23.56$1.89B0.541.26 million shs379,650 shsPRTAProthena$4.78+2.6%$8.70$4.32▼$25.42$257.29M0.11691,122 shs549,184 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFTREFortrea-4.40%+1.72%-34.03%-62.32%-83.73%LFSTLifeStance Health Group-1.18%+7.10%-13.53%-26.68%+5.57%PINCPremier-1.08%-0.87%+11.73%+29.96%+20.82%PRTAProthena+1.53%-29.18%-45.18%-69.06%-77.61%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFTREFortrea3.2189 of 5 stars3.91.00.00.02.60.82.5LFSTLifeStance Health Group2.4305 of 5 stars3.41.00.00.03.42.50.6PINCPremier2.1403 of 5 stars1.02.02.50.03.62.51.9PRTAProthena2.8054 of 5 stars4.21.00.00.02.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFTREFortrea 1.86Reduce$15.00236.32% UpsideLFSTLifeStance Health Group 2.83Moderate Buy$8.5042.14% UpsidePINCPremier 2.00Hold$22.20-3.44% DownsidePRTAProthena 2.33Hold$31.50559.00% UpsideCurrent Analyst Ratings BreakdownLatest PINC, LFST, PRTA, and FTRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025PRTAProthenaBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underperform5/27/2025LFSTLifeStance Health GroupUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.505/27/2025PRTAProthenaPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$110.00 ➝ $81.005/27/2025PRTAProthenaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$78.00 ➝ $29.005/27/2025PRTAProthenaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral5/27/2025PRTAProthenaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$6.005/27/2025PRTAProthenaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/27/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $14.005/27/2025PRTAProthenaChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $18.005/22/2025FTREFortreaCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/21/2025PINCPremierPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$19.00 ➝ $24.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFTREFortrea$2.69B0.15$0.71 per share6.28$19.58 per share0.23LFSTLifeStance Health Group$1.28B1.81N/AN/A$3.77 per share1.59PINCPremier$1.26B1.50$4.42 per share5.20$18.81 per share1.22PRTAProthena$137.94M1.87N/AN/A$10.46 per share0.46Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFTREFortrea-$3.40M-$8.79N/A3.481.78-10.99%2.00%0.80%8/11/2025 (Estimated)LFSTLifeStance Health Group-$186.26M-$0.10N/AN/AN/A-7.90%-6.66%-4.51%8/14/2025 (Estimated)PINCPremier$119.54M$0.57N/A17.29N/A-0.40%9.41%5.38%8/19/2025 (Estimated)PRTAProthena-$147.03M-$2.08N/AN/AN/A-90.50%-22.67%-19.68%8/7/2025 (Estimated)Latest PINC, LFST, PRTA, and FTRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025FTREFortrea-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million5/8/2025Q1 2025PRTAProthena-$0.92-$1.12-$0.20-$1.12$8.18 million$2.83 million3/3/2025Q4 2024FTREFortrea$0.36$0.18-$0.18-$0.68$703.22 million$697.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFTREFortreaN/AN/AN/AN/AN/ALFSTLifeStance Health GroupN/AN/AN/AN/AN/APINCPremier$0.843.65%+2.50%147.37%N/APRTAProthenaN/AN/AN/AN/AN/ALatest PINC, LFST, PRTA, and FTRE DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/24/2025PINCPremierquarterly$0.214.2%5/30/20256/1/20256/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFTREFortrea0.741.181.18LFSTLifeStance Health Group0.191.321.32PINCPremierN/A0.830.83PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFTREFortreaN/ALFSTLifeStance Health Group85.50%PINCPremier74.41%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipFTREFortrea0.12%LFSTLifeStance Health Group3.20%PINCPremier0.96%PRTAProthena9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFTREFortrea18,00090.50 million89.59 millionOptionableLFSTLifeStance Health Group6,640388.88 million357.39 millionOptionablePINCPremier2,60082.34 million90.43 millionOptionablePRTAProthena13053.83 million38.64 millionOptionablePINC, LFST, PRTA, and FTRE HeadlinesRecent News About These CompaniesUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stake in Prothena Co. plc (NASDAQ:PRTA)June 3 at 3:58 AM | marketbeat.comAnalysts Set Prothena Co. plc (NASDAQ:PRTA) Price Target at $31.50June 3 at 2:23 AM | americanbankingnews.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Hold" by BrokeragesJune 1 at 3:25 AM | marketbeat.comFY2025 EPS Estimates for Prothena Cut by Chardan CapitalMay 31 at 6:27 AM | marketbeat.comHC Wainwright Has Weak Outlook for Prothena FY2027 EarningsMay 31 at 2:45 AM | americanbankingnews.comPiper Sandler Reduces Prothena (PRTA) Price Target to $81 from $110 Following AFFIRM-AL Trial DiscontinuationMay 30, 2025 | msn.comChardan Lowers Prothena (PRTA) Price Target Following AFFIRM-AL Trial FailureMay 30, 2025 | msn.comH.C. Wainwright Maintains Buy Rating on Prothena Corporation (NASDAQ:PRTA), Cuts PTMay 30, 2025 | insidermonkey.comFY2027 EPS Estimates for Prothena Decreased by HC WainwrightMay 30, 2025 | marketbeat.comWellington Management Group LLP Increases Position in Prothena Co. plc (NASDAQ:PRTA)May 30, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Given Underperform Rating at Bank of AmericaMay 30, 2025 | americanbankingnews.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 30, 2025 | finance.yahoo.comB of A Securities Downgrades Prothena (PRTA)May 29, 2025 | msn.comProthena (NASDAQ:PRTA) Lowered to Underperform Rating by Bank of AmericaMay 29, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Price Target Cut to $81.00 by Analysts at Piper SandlerMay 29, 2025 | americanbankingnews.comProthena (NASDAQ:PRTA) Stock Rating Lowered by OppenheimerMay 29, 2025 | americanbankingnews.comChardan Capital Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 29, 2025 | americanbankingnews.comJefferies Downgrades Prothena Corporation (PRTA) After Negative Trial ResultsMay 29, 2025 | finance.yahoo.comOppenheimer Downgrades Prothena Corporation (NASDAQ:PRTA) to Perform from OutperformMay 28, 2025 | insidermonkey.comPiper Sandler Issues Pessimistic Forecast for Prothena (NASDAQ:PRTA) Stock PriceMay 28, 2025 | marketbeat.comProthena Target of Unusually High Options Trading (NASDAQ:PRTA)May 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePINC, LFST, PRTA, and FTRE Company DescriptionsFortrea NASDAQ:FTRE$4.46 +0.33 (+7.99%) As of 12:17 PM EasternFortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.LifeStance Health Group NASDAQ:LFST$5.98 +0.10 (+1.70%) As of 12:17 PM EasternLifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.Premier NASDAQ:PINC$22.99 +0.13 (+0.57%) As of 12:15 PM EasternPremier, Inc., together with its subsidiaries, operates as a healthcare improvement company in the United States. It operates in two segments, Supply Chain Services and Performance Services. The Supply Chain Services segment offers its members with an access to a range of products and services, including medical and surgical products, pharmaceuticals, laboratory supplies, capital equipment, information technology, facilities and construction, and food and nutritional products, as well as purchased services, such as clinical engineering and workforce solutions. This segment also provides the ASCENDrive programs for members to receive group purchasing programs, tiers, and prices; SURPASS Performance Group services; and STOCKD, an e-commerce platform, as well as direct sourcing business; SaaS informatics products; supply chain co-management services; purchased services contracts; direct sourcing solutions; and supply chain resiliency programs. The Performance Services segment provides technology and services platform with offerings that help optimize performance in three main areas, including clinical intelligence, margin improvement, and value-based care under the PINC AI brand; third party administrator services and management of health benefit programs under the Contigo Health brand; and digital invoicing and payables services that offers financial support services to healthcare product suppliers and service providers under the Remitra brand. The company was incorporated in 2013 and is based in Charlotte, North Carolina.Prothena NASDAQ:PRTA$4.78 +0.12 (+2.58%) As of 12:17 PM EasternProthena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
